menu
    • menu
    [{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Karolinska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Linc AB","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Linc AB"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Orellanine

    Menu

    Orellanine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncorena Receives FDA Approval to Initiate Studies in the US

                            Details : ONC175 is a synthetically produced orellanine, which is highly specific to the kidney and induces irreversible renal failure. Currently being investigated for renal cell carcinoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncorena's First Patient Treated with ONC175 (Orellanine) in Clinical Phase I/II Trial in Patients with Metast...

                            Details : ONC175 (orellanine) is the highly selective organ-targeted chemotherapy with potent anti-tumor effects metastatic renal cancer. The interim data from phase 1b further strengthens the previously reported promising safety and efficacy data.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 04, 2023

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

                            Details : Orellanine is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 18, 2022

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Karolinska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolin...

                            Details : Phase I-II clinical trial of the first-in-class compound Orellanine, found in mushrooms of the Cortinarius family initiated and demonstrated powerful anti-tumor effects on metastatic kidney cancer in different preclinical models.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 01, 2022

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Karolinska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Linc AB

                            Deal Size : $17.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Oncorena Secures Financing of the Company's Continued Development of Orellanine, a Potential Breakthrough Ther...

                            Details : The capital will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer undergoing dialysis. Orellanine is found in mushrooms of the Cortinarius family.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 23, 2021

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Linc AB

                            Deal Size : $17.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Oncorena

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Me...

                            Details : Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : Orellanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.